Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAOK1 | Q7L7X3 | 6/20 | 1.00 |
| ▸ | TAOK3 | Q9H2K8 | 5/20 | 1.00 |
| ▸ | SLC6A9 | P48067 | 9/20 | 0.72 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654038 | 0.87 | TAOK1 (1.00) | TAOK1TAOK3GPR139MAPT | |
| SCHEMBL14422176 | 0.79 | TAOK1 (0.73) | TAOK1TAOK3MAPTRAB9A | |
| SCHEMBL5654217 | 0.77 | TAOK1 (0.63) | TAOK1TAOK3MAPTRAB9A | |
| SCHEMBL3995786 | 0.74 | TAOK1 (0.59) | TAOK1TAOK3RAB9A | |
| SCHEMBL3103847 | 0.74 | ROCK2 (0.78) | TAOK1TAOK3 | |
| SCHEMBL402544 | 0.73 | TAOK1 (0.58) | TAOK1TAOK3SLC6A9MAPTRAB9A | |
| SCHEMBL403002 | 0.73 | TAOK1 (0.61) | TAOK1TAOK3GPR139MAPTRAB9A | |
| SCHEMBL4660820 | 0.73 | KDM4E (0.67) | TAOK1TAOK3SLC6A9RAB9A | |
| SCHEMBL5642916 | 0.73 | KDM4E (0.67) | TAOK1TAOK3SLC6A9RAB9A | |
| SCHEMBL4659439 | 0.73 | KDM4E (0.67) | TAOK1TAOK3SLC6A9RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | claimed |
| US-20250354151-A1 | INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE | KYOTO PREFECTURAL PUBLIC UNIV CORP (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4534091-A1 | INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250354151-A1 | INHIBITORY AGENT FOR MYOCARDIAL CELL DEATH, AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR MYOCARDIAL DISORDERS OR HEART FAILURE | TNNI3, TNNC1, TNNT2 | TAOK1 7/4885TAOK3 16/4885SLC6A9 4468/4885 |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | TAOK1, TAOK3, MAP3K6 | TAOK1 1/4885TAOK3 2/4885SLC6A9 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.